Photo of Sheheryar Kabraji,  MB, ChB

Sheheryar Kabraji, MB, ChB

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute


sheheryar_kabraji@dfci.harvard.edu

Sheheryar Kabraji, MB, ChB

Dana-Farber Cancer Institute

EDUCATIONAL TITLES

  • Instructor, Medicine, Harvard Medical School
  • Physician, Medical Oncology, Dana-Farber Cancer Institute

DF/HCC PROGRAM AFFILIATION

Research Abstract

Dr Kabraji is a physician-scientist using single cell approaches to understand how cell cycle states contribute to drug resistance and cancer relapse in cancer. He has developed novel approaches to measuring cell cycle states in tissues from mouse models and human tumors. Current efforts are focused on translational validation and mechanistic understanding of quiescent cancer cell heterogeneity within untreated and treated tumors. As a physician at Dana Farber Cancer Institute, Dr Kabraji specializes in the treatment of patients with breast cancer brain metastases.

Publications

Powered by Harvard Catalyst
  • Kabraji S, Ni J, Lin NU, Xie S, Winer EP, Zhao JJ. Drug Resistance in HER2-Positive Breast Cancer Brain Metastases: Blame the Barrier or the Brain? Clin Cancer Res 2018. PubMed
  • Alves CP, Dey-Guha I, Kabraji S, Yeh AC, Talele NP, Solé X, Chowdhury J, Mino-Kenudson M, Loda M, Sgroi D, Borresen-Dale AL, Russnes HG, Ross KN, Ramaswamy S. AKT1low Quiescent Cancer Cells Promote Solid Tumor Growth. Mol Cancer Ther 2018; 17:254-263. PubMed
  • Kabraji S, Solé X, Huang Y, Bango C, Bowden M, Bardia A, Sgroi D, Loda M, Ramaswamy S. AKT1(low) quiescent cancer cells persist after neoadjuvant chemotherapy in triple negative breast cancer. Breast Cancer Res 2017; 19:88. PubMed
  • Kabraji S. Progress requires scientific thinking at all levels. Nature 2004; 432:949. PubMed